DRREDDY

Q2 Results: Profit Climbs 7% on Robust Growth in European Operations

. reported a 7.3% year-on-year increase in net profit for the quarter ended September 2025, reaching ₹1,347 crore, compared to ₹1,256 crore in the corresponding quarter of the previous fiscal, according to its stock exchange filing on Friday. The company’s revenue advanced 9.8% year-on-year to ₹8,828 crore for the same period. “Growth in the second quarter was driven by strong momentum in branded markets and consistent performance from the Nicotine Replacement Therapy (NRT) portfolio, which helped cushion the impact of lower U.S. Lenalidomide sales,” said Co-Chairman and Managing Director G. V. Prasad. Revenue from North America dropped 13% to ₹3,240 crore, mainly due to the decline in Revlimid sales, while the India business expanded 13% year-on-year to ₹1,580 crore. The company’s European segment saw exceptional growth, surging 138% year-on-year, driven by contributions from the recently acquired NRT portfolio, according to a company statement. Meanwhile, emerging markets revenue for the quarter rose 14% year-on-year to ₹1,650 crore.